TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06664021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab combined with S-1
Description: Tislelizumab：200mg q3w iv , lasts for one year. S-1：40mg, 50mg, or 60mg orally twice daily for 4 weeks, depending on body surface area, followed by 2 weeks of rest，lasts four cycles.
Study: NCT06663319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-89402638
Description: JNJ-89402638 will be administered.
Study: NCT06607341

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multi-level, community-digital health promotion intervention
Description: Community level activities:~1. Capacity building for community-based organizations, and~2. Community health workers will facilitate linkage to community resources, including health/social service access referrals and client social support.~Individual level activities:~1. Goal setting and self-monitoring,~2. Tailored feedback,~3. Personalized lifestyle coaching, health and social service referral support, and~4. Digital access and digital health literacy skills building~Social network:~1. Social network-based activities, and~2. Digital health literacy skills building

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-level, community-digital health promotion intervention
Description: Community level activities:~1. Capacity building for community-based organizations, and~2. Community health workers will facilitate linkage to community resources, including health/social service access referrals and client social support.~Individual level activities:~1. Goal setting and self-monitoring,~2. Tailored feedback,~3. Personalized lifestyle coaching, health and social service referral support, and~4. Digital access and digital health literacy skills building~Social network:~1. Social network-based activities, and~2. Digital health literacy skills building
Study: NCT06600412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R3R01
Description: R3R01 is an ATP-binding cassette transporter A1 (ABCA1) inducer, which increases the efflux of cholesterol from the intracellular space in the kidney. Please refer to arm/group description for further information.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Please refer to arm/group description for further information.
Study: NCT06589765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535 tablet
Description: HRS-7535 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535 tablet
Description: HRS-7535 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535 tablet
Description: HRS-7535 tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dapagliflozin tablet
Description: dapagliflozin tablet
Study: NCT06590077

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aromatherapy
Description: The test intervention is an aromatherapy cosmetic product containing a blend of 5 essential oils (orange, lavender, frankincense, vetiver, and neroli), diluted in apricot kernel oil. It was formulated by a clinical aromatherapist. Each participant will be asked to use the product every evening over 4 weeks and to complete a validated questionnaire at 3 time points: at the beginning, midway after 2 weeks and at the end of the 4-week study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (placebo) group
Description: Juniper essential oil in apricot kernel oil in low concentration with a faint aroma - presentation as a rollerball. Each participant will be asked to use the product every evening over 4 weeks and to complete a validated questionnaire at 3 time points: at the beginning, midway after 2 weeks and at the end of the 4-week study.
Study: NCT06611228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidomain Interventions
Description: Multidomain Interventions The intervention group will receive a personalized MDI approach from a multidisciplinary team, including a digital coach, physiotherapist, clinical nutrition expert, neuropsychologist, geriatrician, and nurse. This approach will encompass physical activity program, nutritional interventions, cognitive training and stimulation, medication reconciliation, coaching on the use of technological supports, and group activities. Environmental modifications at home will also be proposed
Study: NCT06086613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGA2115
Description: In Part A, participants will receive AGA2115 as a single dose administered as a subcutaneous (SC) injection (5 cohorts) or as an intravenous (IV) infusion (1 cohort).~In Part B, participants will receive AGA2115 in multiple doses administered as a SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In Part A, participants will receive single dose of placebo administered as a SC injection (5 cohorts) or IV infusion (1 cohort).~In Part B, participants will receive multiple doses of placebo administered as a SC injection.
Study: NCT06612125

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: volume controlled ventilation
Description: Pediatric patients in the VCV group (n= 30) received volume-controlled ventilation, target tidal volume was set at 7 mL/kg, with a respiratory rate of 16 breaths/min and a respiratory ratio of 1:2.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pressure controlled ventilation
Description: Pediatric patients in the PCV group(n=30) received pressure-controlled ventilation. The initial parameters will be as follows: the peak inspiratory pressure (PIP) will set to provide a tidal volume of 7 ml/kg , respiratory rate will be 16 breaths/min, inspiratory to expiratory ratio was 1:2 with an upper limit of PIP of 20 cm H2O.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pressure controlled volume grantanteed ventilation
Description: Pediatric patients in the PCV-VG group (n=30)will be conducted with pressure-controlled volume-guaranteed ventilation, target tidal volume will set at 7 mL/kg, with a respiratory rate of 16 breaths/min and a respiratory ratio of 1:2.
Study: NCT06518057

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo CSF sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT and/or CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Craniospinal Irradiation
Description: Undergo proton CSI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Volume Modulated Arc Therapy
Description: Undergo photon VMAT CSI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hippocampal-Avoidance Craniospinal Irradiation
Description: Undergo HA
Study: NCT05164172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: Concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: Concentrate for solution for infusion
Study: NCT04739059

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL312
Description: Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody
Study: NCT06398470

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: NeuroSAFE procedure
Description: Frozen section analysis of the posterolateral surface of the prostate to guide nerve sparing decisions.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: LaserSAFE procedure
Description: The LaserSAFE procedure is performed using an FCM called the Histolog® scanner developed by Samantree® which can be placed within the operating room. The Histolog® scanner produces digital images with high, micrometre-range resolution and enables the visualization of tissue microstructures down to the cellular level.
Study: NCT06675565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-AGT01 RVR
Description: ALN-AGT01 RVR will be administered subcutaneously (SC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered SC
Study: NCT05731492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan will be administered orally.
Study: NCT06625008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D-printed model
Description: The Department of Radiology at Vanderbilt University Medical Center will create a 3D-printed human torso model that includes the colon, rectum, and a stoma on the abdominal wall. This model will be used to provide pre-operative counseling during the surgical consent for patients.
Study: NCT03861676

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Focal brachytherapy with PSMA PET imaging
Description: Focal brachytherapy with PSMA PET imaging. Focal (partial prostate gland) brachytherapy following 18F-DCFPyl PET/CT radiotracer imaging. Patients will also undergo pre-treatment transperineal mapping biopsy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (18F)DCFPyL
Description: 18F-DCFPyl PET/CT scan
Study: NCT06624709

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Supplement
Description: The interventional group will receive 2-3mg/kg/day of iron supplementation 4 times per week and the sham comparator will receive 2-3mg/kg/day of iron supplementation 7 times per week

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Iron Supplement
Description: The interventional group will receive 2-3mg/kg/day of iron supplementation 4 times per week and the sham comparator will receive 2-3mg/kg/day of iron supplementation 7 times per week
Study: NCT06626438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatable traits model of care
Description: Embedded multidisciplinary clinic with treatable traits model of care.
Study: NCT05340582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen Injection
Description: Acetaminophen injection solution 1000 mg/100 mL (10 mg/mL) latex-free plastic bag - dosage for this protocol is 15mg/kg/dose IV four times a day for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 20 mg/mL oral suspension or Ibuprofen lysine 10 mg/mL injection solution (Neoprofen)
Description: Ibuprofen is not a study drug - standard of care in participating NICUs in the standard clinical dose for neonates (typically, for neonates \< 7 days old - 10 mg/kg/dose on day 1, 5 mg/kg/dose q24h on days 2 and 3; for neonates \> 7 days old - 20 mg/kg/dose on day 1, 10 mg/kg/dose q24h on days 2 and 3)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen 20 mg/mL oral suspension or Ibuprofen lysine 10 mg/mL injection solution (Neoprofen)
Description: Ibuprofen is not a study drug - standard of care in participating NICUs in the standard clinical dose for neonates (typically, for neonates \< 7 days old - 10 mg/kg/dose on day 1, 5 mg/kg/dose q24h on days 2 and 3; for neonates \> 7 days old - 20 mg/kg/dose on day 1, 10 mg/kg/dose q24h on days 2 and 3)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride 0.9% injection
Description: Placebo- IV q6h for 3 days
Study: NCT06713577

Intervention type: DEVICE
Intervention: CEREC Cercon 4D
Description: One investigational medical device is a new generation of a full contour zirconia restorative material (CEREC Cercon 4D/Dentsply Sirona) for chairside computer assisted design/computer assisted machines (CAD/CAM) restorations. It has an internal core of 4 mol% (4Y) zirconia transitioning to an external layer of 4/5 mol% (4/5 Y) zirconia with a three-dimensional gradient of shade from an inner chromatic layer to an external translucent layer that replicates the natural structure and appearance of a tooth. It is indicated for crowns, bridges, veneers, inlays and onlays and implant crowns Clinical Study of a 3D Shaded Zirconia for Chairside CAD/CAM Restorations The other investigational medical devices are a universal bonding agent (Prime and Bond Active/Dentsply Sirona) and dual-cure, self-adhesive resin cement (Calibra Universal~+/Dentsply Sirona). They are used in combination to deliver ceramic and zirconia restorations.

Intervention type: DEVICE
Intervention: CEREC Cercon 4D
Description: One investigational medical device is a new generation of a full contour zirconia restorative material (CEREC Cercon 4D/Dentsply Sirona) for chairside computer assisted design/computer assisted machines (CAD/CAM) restorations. It has an internal core of 4 mol% (4Y) zirconia transitioning to an external layer of 4/5 mol% (4/5 Y) zirconia with a three-dimensional gradient of shade from an inner chromatic layer to an external translucent layer that replicates the natural structure and appearance of a tooth. It is indicated for crowns, bridges, veneers, inlays and onlays and implant crowns Clinical Study of a 3D Shaded Zirconia for Chairside CAD/CAM Restorations The other investigational medical devices are a universal bonding agent (Prime and Bond Active/Dentsply Sirona) and dual-cure, self-adhesive resin cement (Calibra Universal~+/Dentsply Sirona). They are used in combination to deliver ceramic and zirconia restorations.
Study: NCT06719531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring
Description: CGM and frequent sample testing
Study: NCT06723158

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) glasses with relaxation module
Description: The relaxation module will include immersive video and audio components as a distraction from the medical procedures.
Study: NCT06732531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH011
Description: BH011 is administered intravesically through a urinary catheter and is retained in the bladder for 1 hour. It was administered once a week for 6 weeks during the induction treatment period and once a month for 12 months during the maintenance treatment period.
Study: NCT06733441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLN-254
Description: TLN-254 will be administered orally at a specified dose on specified days depending on treatment allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLN-254
Description: TLN-254 will be administered orally at a specified dose on specified days.
Study: NCT06735248

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1195
Description: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1195
Description: IM injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IM injection
Study: NCT06756607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SUPPORT toolkit
Description: The SUPPORT toolkit comprises of the SUPPORT CT website and interaction with a SUPPORT navigator.
Study: NCT06749288

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Radicle Revive Placebo Control Form 4.1
Description: Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Radicle Revive Active Study Product 4.1 Usage
Description: Participants will use their Radicle Revive Active Study Product 1.1 as directed for a period of 6 weeks.
Study: NCT06753097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous finger-cuff arterial pressure monitoring
Description: Arterial pressure will be monitored using continuous non-invasive finger-cuff arterial pressure monitoring.
Study: NCT06755450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUR112
Description: Once daily
Study: NCT06765642

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: The use of this approach aims to potentially maximize motor recovery in chronic stroke by harnessing corticospinal plasticity and modulating motor learning behavior.
Study: NCT06765213

Intervention type: DIAGNOSTIC_TEST
Intervention: Open Ended Oral Food Challenge
Description: Allergens determined to be sensitized will be brought in for an oral challenge to that food.

Intervention type: DIAGNOSTIC_TEST
Intervention: Open Ended Oral Food Challenge
Description: Allergens determined to be sensitized will be brought in for an oral challenge to that food.

Intervention type: OTHER
Intervention: Early Introduction
Description: Infants that are not sensitized will have the food introduced to their diet at regular intervals.

Intervention type: OTHER
Intervention: Early Introduction
Description: Infants that are not sensitized will have the food introduced to their diet at regular intervals.
Study: NCT06761768

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Corticosteroids Triamcinolone Acetonide
Description: ultrasound-guided sacroiliac joint corticosteroid injections (1 ml SHINCORT INJ 10 MG/ML + 1 ml 2% Xylocaine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids Triamcinolone Acetonide
Description: ultrasound-guided sacroiliac joint corticosteroid injections (1 ml SHINCORT INJ 10 MG/ML + 1 ml 2% Xylocaine)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal shockwave
Description: a three-week course of weekly extracorporeal shockwave therapy sessions (intensity: low to moderate, adjusted based on patient tolerance; frequency: 5 Hz; 2000 shocks per session)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: extracorporeal shockwave(minimum intensity)
Description: a three-week course of weekly extracorporeal shockwave therapy sessions (intensity: minimum setting on the device; frequency: 5 Hz; 2000 shocks per session)
Study: NCT06762301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sexual education and counseling
Description: After the initial evaluation, pregnant women who will be included in the study group will be given an appointment for 1 week later, they will be asked to come with their partners and couples will be given sexual education and counseling in line with the PLISSIT model. After the initial evaluation, couples will be interviewed in the 1st, 2nd and 3rd trimesters, their sexuality since the previous evaluation according to the PLISSIT model, their problems, if any, will be discussed and short counseling will be given if necessary. In the first 4 weeks after delivery, couples in the study group will receive sexual education and counseling for the postpartum period in line with the PLISSIT model. They will be interviewed at the 3rd and 6th month after delivery and their postpartum sexuality and problems, if any, will be discussed and the sexual functions of the couples for the last 4 weeks will be evaluated.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine clinical care
Description: Control Group
Study: NCT06765681

Intervention type: OTHER
Intervention: Diagnosis of both VTE and sepsis
Description: Both diagnoses need to present during ICU stay for case inclusion into this retrospective study

Intervention type: OTHER
Intervention: Diagnosis of both VTE and sepsis
Description: Both diagnoses need to present during ICU stay for case inclusion into this retrospective study

Intervention type: OTHER
Intervention: Diagnosis of both VTE and sepsis
Description: Both diagnoses need to present during ICU stay for case inclusion into this retrospective study
Study: NCT06766591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivonescimab combined with chemotherapy
Description: Ivonescimab combined with chemotherapy. The specific chemotherapy regimen is based on the real world.
Study: NCT06766474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: to our knowledge, this study is the 1st to compare the efficacy of bupivacaine hydrochloride-soaked dressing versus subcutaneous infiltration for postoperative donor site pain control for patients undergoing STSG procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: to our knowledge, this study is the 1st to compare the efficacy of bupivacaine hydrochloride-soaked dressing versus subcutaneous infiltration for postoperative donor site pain control for patients undergoing STSG procedures.
Study: NCT06765629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive Percutaneous Tibial Nerve Stimulation (TTNS) group
Description: After obtaining informed consent from the subjects, the researchers screen the subjects based on the inclusion and exclusion criteria. The wearable non-invasive percutaneous tibial nerve stimulator is placed on the area where the tibial nerve runs at the medial malleolus of the subjects. Once the wearable stimulator is properly fitted, stimulation parameter programming and treatment record management are conducted through the programming software running on the mobile phone.
Study: NCT06767332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eye movement desensitization and reprocessing (EMDR)
Description: EMDR is a psychological intervention that has historically been applied to the treatment of Post-Traumatic Stress Disorder (PTSD), but has since then been shown to be effective for a variety of anxiety disorders (e.g. fear of illness and specific phobia) (Logie \& de Jongh, 2014) and somatic complaints such as post-operative pain, medically unexplained symptoms and seizure-related post-traumatic stress (Dautovic, de Roos, van Rood, Dommerholt, \& Rodenburg, 2016; van Rood \& de Roos, 2009; Maroufi, Zamani, Izadikhah, Marofi, \& O'Connor, 2016).~With more than 25 randomized clinical trials, EMDR has been established as an evidence-based intervention for PTSD and PTSD symptomatology including physical symptoms and fear of future catastrophes (Balkom van et al., 2013).
Study: NCT06767124

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ketogenic Supplement
Description: Commercially available ketone ester drink

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Drink
Description: Placebo drink containing sunflower oil.
Study: NCT06765902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: A subcutaneous injection of an IL-15 superagonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETBX-071
Description: A subcutaneous injection of a prostate-specific antigen (PSA) adenovirus vaccine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M-CENK
Description: An intravenous infusion of the patient's own NK cells that have been expanded and activated in a laboratory.